Global Digestive and Intestinal Remedies market share 2024, Forecast To 2033
4 Mar, 2024
The digestive and intestinal remedies market size has grown strongly, increasing from$20.51 billion in 2023 to$21.63 billion in 2024, showcasing a compound annual growth rate (CAGR) of 5.4%. The historic growth is attributed to traditional remedies, lifestyle changes, increased stress levels, dietary shifts, and the impact of COVID-19. Forecasts indicate continued strong growth, with the market projected to reach$27.36 billion by 2028, boasting a compound annual growth rate (CAGR) of 6.1%. This growth is attributed to healthcare accessibility, global health events, rising health consciousness, the aging population, and innovative product development. Major trends in the forecast period encompass healthcare access, environmental factors, consumer education, regulatory environment, and pharmaceutical advancements.
Global Digestive and Intestinal Remedies Market Key Driver
The increase in gastrointestinal disorder cases is expected to propel the digestive and intestinal remedy market going forward. Gastrointestinal disorders refer to a collective term of diseases such as nausea, vomiting, food poisoning, and diarrhea that impact the overall biological functioning of the gastrointestinal (GI) tract. The rising incidence of gastrointestinal disorders has resulted in a growing demand for digestive and intestinal remedies that can treat gastrointestinal diseases effectively. For instance, in May 2021, according to a report published by BioMed Central, a UK-based journal, the prevalence of Inflammatory Bowel Disease (IBD) is expected to significantly increase in various regions in 2035. Iran is projected to experience a 2.5-fold rise, reaching 69 thousand cases. In North Africa and the Middle East, the prevalence is estimated to increase by 2.3-fold, totaling 220 thousand cases. Moreover, there is an anticipation of a fourfold increase in prevalence in India, totaling 2.2 million cases. The East Asia region is anticipated to experience a 1.5-fold increase, reaching 4.5 million cases, while high-income Asia-Pacific and Southeast Asia regions are expected to have a 1.6-fold elevation in prevalence, with 183 thousand and 199 thousand cases, respectively. Therefore, an increase in gastrointestinal disorder cases is expected to drive the growth of the digestive and intestinal remedy market. In 2023, the digestive and intestinal remedy market reached $7.8 billion, and it is anticipated to grow to $12.4 billion by 2028.
Get A Free Sample Of The Global Digestive and Intestinal Remedies Market ReportGlobal Digestive and Intestinal Remedies Market Segments
The global digestive and intestinal remedies market covered in this report is segmented –
1) By Type: Digestive Medicines, Remedies Against Gastrointestinal Complaints, Natural And Synthetic Agents
2) By Age Group: Pediatric, Adults
3) By Distribution Channel: Online, Offline
By Geography: The regions covered in the digestive and intestinal remedies market report are Asia-Pacific, Western Europe, Eastern Europe,North America, South America, Middle East, and Africa.
North America was the largest region in the digestive and intestinal remedies market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the digestive and intestinal remedies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Major Digestive and Intestinal Remedies Industry Players
Bayer AG, Abbott Laboratories, Bausch Health Companies Inc., CH Boehringer Sohn AG & Co. KG, Eli Lilly and Company, GlaxoSmithKline PLC, Jiangzhong Pharmaceutical Co. Ltd., Johnson & Johnson Pvt. Ltd., Menarini Group, Merck Co. & KGaA, Pfizer Inc., Prestige Consumer Healthcare Inc., Procter & Gamble Company, Reckitt Benckiser Group PLC, Sanofi SA, Takeda Pharmaceutical Company Limited, AbbVie Inc., Alfa Wassermann and Sigma-Tau, Allergan PLC, AstraZeneca PLC, Boehringer Ingelheim International GmbH, Daiichi Sankyo Chemical Pharma Co. Ltd., Evoke Pharma Inc., Ipsen SA, Ironwood Pharmaceuticals Inc., Mundipharma, Mylan NV, Norgine Pharmaceuticals Ltd., Novartis AG, Otsuka Pharmaceutical Co. Ltd., Perrigo Company, Recordati S.p.A., RedHill Biopharma Ltd., Ritter Pharmaceuticals Inc., Salix Pharmaceuticals Inc.
Get The Full Global Digestive and Intestinal Remedies Market Report
Digestive and Intestinal Remedies Market Overview
The digestive and intestinal remedy refers to medications that can treat gastrointestinal disorders such as stomach upset, constipation, and diarrhoea. It uses classes of drugs such as antacids, proton pump inhibitors, and histamine2 blockers during the treatment process.
Digestive and Intestinal Remedies Global Market Report 2023 provides data on the global digestive and intestinal remedies market such as market size, growth forecasts, segments and geographies, competitive landscape including leading competitors’ revenues, profiles and market shares. The digestive and intestinal remedies market report identifies opportunities and strategies based on market trends and leading competitors’ approaches.